鹿得医疗(832278) - 2024 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders for the first nine months of 2024 was CNY 18,397,981.89, a decrease of 29.99% from CNY 26,278,954.51 in the same period of 2023[4] - Operating revenue for the first nine months of 2024 was CNY 234,676,473.81, down 1.44% from CNY 238,100,590.72 year-on-year[4] - The company reported a decrease in inventory to CNY 70,766,362.09 from CNY 67,033,614.87, an increase of approximately 4.09%[14] - The gross profit margin for the first nine months of 2024 is approximately 23.0%, down from 26.0% in the same period of 2023[22] - The company reported a total profit of CNY 23,372,069.72 for the first nine months of 2024, compared to CNY 29,187,526.42 in the same period of 2023, reflecting a decrease of approximately 20.0%[22] Cash Flow - The net cash flow from operating activities for the first nine months of 2024 was CNY 19,430,378.78, a decline of 17.90% compared to CNY 23,668,157.57 in the previous year[4] - Cash inflow from investment activities totaled CNY 139,174,074.48, a decline of 49.5% compared to CNY 275,752,303.02 in the previous year[26] - Net cash flow from investment activities was -CNY 12,574,023.92, improving from -CNY 21,449,506.71 year-on-year[26] - Cash inflow from financing activities was CNY 26,873,097.50, an increase from CNY 21,050,000.00 in the same period last year[26] - Net cash flow from financing activities was -CNY 6,145,208.29, an improvement from -CNY 21,364,529.58 year-on-year[26] Assets and Liabilities - Total assets as of September 30, 2024, reached CNY 505,456,403.10, an increase of 3.01% compared to CNY 490,678,552.02 at the end of 2023[4] - The company's asset-liability ratio (consolidated) was 22.62%, up from 20.59% at the end of 2023[4] - Total liabilities rose to CNY 114,348,324.84 from CNY 101,008,234.16, indicating an increase of approximately 13.18%[16] - The company’s total equity increased to CNY 391,108,078.26 from CNY 389,670,317.86, a growth of about 0.37%[16] - Current assets decreased to CNY 324,603,731.72 from CNY 339,190,391.65, a decline of about 4.29%[14] Shareholder Information - The total number of ordinary shares at the end of the period was 176,000,000, with 6,093 shareholders[8] - The top ten shareholders collectively hold 71.61% of the shares, with the largest shareholder owning 22.23%[9] - There are no pledged or judicially frozen shares among the top ten shareholders[10] Investment and Financing - The company experienced a 172.41% increase in receivables financing, reaching CNY 1,869,860.80, primarily due to an increase in held receivable notes[5] - Investment income decreased by 90.03% to CNY 318,172.58, mainly due to a decline in the performance of an associated company[5] - Cash flow from investing activities decreased by 41.38% to -¥12,574,023.92, attributed to the redemption of financial products purchased with idle funds in the previous period[6] Research and Development - Research and development expenses for the first nine months of 2024 were CNY 10,440,204.85, nearly unchanged from CNY 10,446,983.34 in the same period of 2023[20]